-
FDA Approves Clovis Oncology's Ovarian Cancer Treatment
Monday, December 19, 2016 - 11:53am | 381Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS) soared higher by more than 15 percent Monday after the U.S. Food and Drug Administration granted an accelerated approval for the company's PARP inhibitor rucaparib for the treatment of women with advanced ovarian cancer which will now be branded...
